Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Doebele, MD
Boundless Bio, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sarcoma Oncology Research Center
Santa Monica, California, United States
- Start Midwest
Grand Rapids, Michigan, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Next Oncology
Irving, Texas, United States
- Next Oncology
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Mar 2024
- Primary completion
- 25 Jun 2025
- Completion
- 25 Jun 2025
- Last update posted
- 8 Jun 2026
- Registered enrollment
- 19
- Registry id
- NCT06299761
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.